MindImmune Therapeutics’ Issuance and Sale of $12.4 Million Series A Convertible Preferred Stock

Martina Bellini
Tagged:

Locke Lord advised MindImmune Therapeutics, Inc. on the deal.MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to treat Alzheimer’s disease and other neuro-degenerative…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here